Musculoskeletal scientific sessions at the RSNA meeting will address the use of dual-energy CT in multiple settings, including the possibility of combined heart and bone density scans. Submitted papers also show the use of dual-energy CT for imaging other indications, such as gout.
Musculoskeletal scientific sessions at the RSNA meeting will address the use of dual-energy CT in multiple settings, including the possibility of combined heart and bone density scans. Submitted papers also show the use of dual-energy CT for imaging other indications, such as gout.
"When we do a dual-energy CT scan it requires a lot of time and a lot of imaging and so the question becomes what else can we use that data for?" said Dr. Michelle Barr, RSNA musculoskeletal subcommittee chair and associate professor of radiology at the University of Virginia Health Systems in Charlottesville.
"Maybe we can study bone density at the same time because the population that tends to have cardiac disease also tends to have osteoporosis," she said. "So we can do two things with one study."
A use for dual-energy CT not explored before involves the identification of gout crystals. Papers demonstrate the ability of imaging to quantify gout crystals and also determine whether the crystals start to decrease in soft tissues post-treatment.
"In the past it's taken 10 years of observing radiographic evidence closely in a patient before we can actually see any findings that confirm gout," Barr said.
Previously a clinician would try to diagnose gout by looking at levels of uric acid in the blood. But often that level is normal in gout patients.
"This is a great breakthrough because it confirms if someone is having problems with gout. We're excited to see there actually is a tool that may be able to diagnosis it early," Barr said.
Another paper looks at the effects of medication on neurotransmitters, specifically how medications affect the transmission of impulses in peripheral nerves.
"As we're getting more and more medications similar to each other for treatment of different diseases, I think this ability to evaluate neurotransmitters and transmitters in peripheral nerves will really affect clinical practice," she said.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.